AR106687A1 - PROCESO PARA PREPARAR UNA FORMULACIÓN EN POLVO SECO QUE COMPRENDE UN ANTICOLINÉRGICO, UN CORTICOSTEROIDE Y UN b-ADRENÉRGICO - Google Patents
PROCESO PARA PREPARAR UNA FORMULACIÓN EN POLVO SECO QUE COMPRENDE UN ANTICOLINÉRGICO, UN CORTICOSTEROIDE Y UN b-ADRENÉRGICOInfo
- Publication number
- AR106687A1 AR106687A1 ARP160103472A ARP160103472A AR106687A1 AR 106687 A1 AR106687 A1 AR 106687A1 AR P160103472 A ARP160103472 A AR P160103472A AR P160103472 A ARP160103472 A AR P160103472A AR 106687 A1 AR106687 A1 AR 106687A1
- Authority
- AR
- Argentina
- Prior art keywords
- corticosteroid
- dry powder
- formulation
- adrenergic
- polynergic
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/194—Carboxylic acids, e.g. valproic acid having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
- A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Pulmonology (AREA)
- Molecular Biology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Biophysics (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Pain & Pain Management (AREA)
- Otolaryngology (AREA)
- Biochemistry (AREA)
- Rheumatology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Formulación en polvo seco para inhalación que comprende una combinación de un anticolinérgico, un agonista del receptor adrenérgico b2 de acción prolongada, y, opcionalmente, un corticosteroide para inhalación, y con un proceso para la preparación de la misma. Reivindicación 6: El proceso de acuerdo con la reivindicación 1 ó 2, en donde el fármaco antimuscarínico es bromuro de glicopirronio, el ICS es dipropionato de beclometasona, el LABA es fumarato de formoterol dihidrato.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP15194661 | 2015-11-16 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR106687A1 true AR106687A1 (es) | 2018-02-07 |
Family
ID=54548063
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP160103472A AR106687A1 (es) | 2015-11-16 | 2016-11-14 | PROCESO PARA PREPARAR UNA FORMULACIÓN EN POLVO SECO QUE COMPRENDE UN ANTICOLINÉRGICO, UN CORTICOSTEROIDE Y UN b-ADRENÉRGICO |
Country Status (32)
Country | Link |
---|---|
US (3) | US10086003B2 (es) |
EP (2) | EP3689379B1 (es) |
JP (1) | JP6942126B2 (es) |
KR (1) | KR20180082442A (es) |
CN (1) | CN108348614B (es) |
AR (1) | AR106687A1 (es) |
AU (1) | AU2016357988B2 (es) |
CA (1) | CA3005291C (es) |
CL (1) | CL2018001297A1 (es) |
CO (1) | CO2018005139A2 (es) |
DK (2) | DK3689379T3 (es) |
EA (1) | EA037346B1 (es) |
ES (2) | ES2890409T3 (es) |
GE (1) | GEP20207178B (es) |
HK (1) | HK1256859A1 (es) |
HR (2) | HRP20211599T1 (es) |
HU (2) | HUE050343T2 (es) |
IL (1) | IL259327B (es) |
MA (1) | MA52437A (es) |
MX (1) | MX2018005979A (es) |
MY (1) | MY198321A (es) |
PE (1) | PE20181377A1 (es) |
PH (1) | PH12018501023B1 (es) |
PL (2) | PL3377109T3 (es) |
PT (2) | PT3377109T (es) |
SA (1) | SA518391574B1 (es) |
SG (2) | SG10201912090UA (es) |
SI (2) | SI3377109T1 (es) |
TW (1) | TWI729025B (es) |
UA (1) | UA125173C2 (es) |
WO (1) | WO2017085007A1 (es) |
ZA (1) | ZA201803167B (es) |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA3059824A1 (en) | 2017-05-11 | 2018-11-15 | Chiesi Farmaceutici S.P.A. | A process for preparing a dry powder formulation comprising an anticholinergic, a corticosteroid and a beta-adrenergic |
KR102637303B1 (ko) * | 2017-05-11 | 2024-02-20 | 키에시 파르마슈티시 엣스. 피. 에이. | 항콜린제, 코르티코스테로이드 및 베타-아드레날린성 약물을 포함하는 건조 분말 제제의 제조 방법 |
WO2019060595A1 (en) * | 2017-09-20 | 2019-03-28 | Teva Branded Pharmaceutical Products R&D, Inc. | INHALABLE DRY POWDER MEDICINAL PRODUCT COMPRISING GLYCOPYRRONIUM |
CN112823009A (zh) * | 2019-08-28 | 2021-05-18 | 上海谷森医药有限公司 | 糠酸氟替卡松脂质体制剂及其制备方法 |
CN116194087A (zh) * | 2020-01-15 | 2023-05-30 | 四川海思科制药有限公司 | 一种含茚达特罗的吸入气雾剂药物组合物及其制备方法 |
CN111467498A (zh) * | 2020-05-14 | 2020-07-31 | 王兆霖 | 药物组合物制剂 |
CN117064869A (zh) * | 2023-09-27 | 2023-11-17 | 山东京卫制药有限公司 | 一种胶囊型吸入粉雾剂及其制备方法 |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PE20011227A1 (es) * | 2000-04-17 | 2002-01-07 | Chiesi Farma Spa | Formulaciones farmaceuticas para inhaladores de polvo seco en la forma de aglomerados duros |
GB0015043D0 (en) | 2000-06-21 | 2000-08-09 | Glaxo Group Ltd | Medicament dispenser |
ATE326251T1 (de) | 2002-07-31 | 2006-06-15 | Chiesi Farma Spa | Pulverinhalator |
JP2009514779A (ja) * | 2003-07-11 | 2009-04-09 | グラクソ グループ リミテッド | 医薬製剤 |
GB0410399D0 (en) * | 2004-05-10 | 2004-06-16 | Arakis Ltd | The treatment of respiratory disease |
RU2580312C2 (ru) | 2010-04-21 | 2016-04-10 | КЬЕЗИ ФАРМАЧЕУТИЧИ С.п.А. | Способ получения частиц с пониженным электростатическим зарядом |
US9393202B2 (en) | 2013-04-26 | 2016-07-19 | Chiesi Farmaceutici S.P.A | Particle size reduction of an antimuscarinic compound |
SI3019153T1 (sl) * | 2013-07-11 | 2018-12-31 | Chiesi Farmaceutici S.P.A. | Formulacija suhega praška, obsegajoča antiholinergik, kortikosteroid in beta-adrenergik, za dajanje z inhalacijo |
-
2016
- 2016-11-14 DK DK20156815.1T patent/DK3689379T3/da active
- 2016-11-14 GE GEAP201614782A patent/GEP20207178B/en unknown
- 2016-11-14 HU HUE16801984A patent/HUE050343T2/hu unknown
- 2016-11-14 SI SI201630738T patent/SI3377109T1/sl unknown
- 2016-11-14 AU AU2016357988A patent/AU2016357988B2/en active Active
- 2016-11-14 ES ES20156815T patent/ES2890409T3/es active Active
- 2016-11-14 JP JP2018524831A patent/JP6942126B2/ja active Active
- 2016-11-14 AR ARP160103472A patent/AR106687A1/es unknown
- 2016-11-14 MY MYPI2018000703A patent/MY198321A/en unknown
- 2016-11-14 PL PL16801984T patent/PL3377109T3/pl unknown
- 2016-11-14 ES ES16801984T patent/ES2789365T3/es active Active
- 2016-11-14 TW TW105137047A patent/TWI729025B/zh active
- 2016-11-14 HR HRP20211599TT patent/HRP20211599T1/hr unknown
- 2016-11-14 PT PT168019842T patent/PT3377109T/pt unknown
- 2016-11-14 CN CN201680066805.3A patent/CN108348614B/zh active Active
- 2016-11-14 MA MA052437A patent/MA52437A/fr unknown
- 2016-11-14 WO PCT/EP2016/077566 patent/WO2017085007A1/en active Application Filing
- 2016-11-14 DK DK16801984.2T patent/DK3377109T3/da active
- 2016-11-14 CA CA3005291A patent/CA3005291C/en active Active
- 2016-11-14 SG SG10201912090UA patent/SG10201912090UA/en unknown
- 2016-11-14 PL PL20156815T patent/PL3689379T3/pl unknown
- 2016-11-14 EP EP20156815.1A patent/EP3689379B1/en active Active
- 2016-11-14 PT PT201568151T patent/PT3689379T/pt unknown
- 2016-11-14 PE PE2018000972A patent/PE20181377A1/es unknown
- 2016-11-14 UA UAA201805272A patent/UA125173C2/uk unknown
- 2016-11-14 HU HUE20156815A patent/HUE056402T2/hu unknown
- 2016-11-14 SG SG11201804048WA patent/SG11201804048WA/en unknown
- 2016-11-14 EA EA201890967A patent/EA037346B1/ru unknown
- 2016-11-14 EP EP16801984.2A patent/EP3377109B1/en active Active
- 2016-11-14 SI SI201631330T patent/SI3689379T1/sl unknown
- 2016-11-14 KR KR1020187013284A patent/KR20180082442A/ko unknown
- 2016-11-14 MX MX2018005979A patent/MX2018005979A/es active IP Right Grant
- 2016-11-15 US US15/351,510 patent/US10086003B2/en active Active
-
2018
- 2018-05-14 IL IL259327A patent/IL259327B/en active IP Right Grant
- 2018-05-14 CL CL2018001297A patent/CL2018001297A1/es unknown
- 2018-05-14 ZA ZA2018/03167A patent/ZA201803167B/en unknown
- 2018-05-14 SA SA518391574A patent/SA518391574B1/ar unknown
- 2018-05-15 PH PH12018501023A patent/PH12018501023B1/en unknown
- 2018-05-16 CO CONC2018/0005139A patent/CO2018005139A2/es unknown
- 2018-08-27 US US16/113,051 patent/US10786451B2/en active Active
- 2018-12-12 HK HK18115947.2A patent/HK1256859A1/zh unknown
-
2020
- 2020-04-08 HR HRP20200571TT patent/HRP20200571T1/hr unknown
- 2020-08-06 US US16/986,796 patent/US10959944B2/en active Active
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR106687A1 (es) | PROCESO PARA PREPARAR UNA FORMULACIÓN EN POLVO SECO QUE COMPRENDE UN ANTICOLINÉRGICO, UN CORTICOSTEROIDE Y UN b-ADRENÉRGICO | |
ECSP17007538A (es) | 2-(morfolin-4-il)-1,7-naftiridinas | |
AR106688A1 (es) | PROCESO PARA PREPARAR UNA FORMULACIÓN EN POLVO SECO QUE COMPRENDE UN ANTICOLINÉRGICO, UN CORTICOSTEROIDE Y UN b-ADRENÉRGICO | |
CL2015000744A1 (es) | Combinación de regorafenib y ácido acetilsalicílico para el tratamiento del cáncer. | |
CR20190394A (es) | Compuestos de inhibidores de autotaxina | |
BR112016013485A2 (pt) | Método para preparar um produto lácteo tendo teor estável de galacto-oligossacarídeo(s) | |
DOP2017000107A (es) | Diamino-quinoleina 2,4 sustituida como nuevos agentes anticancerigenos | |
CR20170077A (es) | Derivados de heterociclilo opcionalmente condensados de pirimidina útiles para el tratamiento de enfermedades inflamatorias, metabólicas, oncológicas y autoinmunitarias | |
CO2017008031A2 (es) | Compuestos con actividad antagonista de los receptores muscarínicos y actividad agonista del receptor beta2 adrenérgico | |
BR112018072113A2 (pt) | excipiente à base de proteínas para ingredientes farmacêuticos ativos | |
CL2016002848A1 (es) | Combinaciones de bromuro de tiotropio, formoterol y budesonida para el tratamiento de la copd | |
PE20151759A1 (es) | Imidazopiridazinas sustituidas | |
DOP2017000146A (es) | Pirazolpiridinaminas como inhibidores de mknk1 y mknk2 | |
UY35199A (es) | Nuevos derivados carbamato de ciclohexilo y quinuclidinilo que tienen actividad como agonistas beta2 adrenérgicos y como antagonistas muscarínicos M3 | |
AR100784A1 (es) | Micropartículas multicomponentes para usar en una formulación inhalable, proceso para preparar, formulación farmacéutica, inhalador | |
CL2018002200A1 (es) | Administración combinada de un agente de penetración y un compuesto de azufre que contiene compuesto para las plantas. | |
CL2016001429A1 (es) | Formas polimórficas de un compuesto similar a un esteroide y metodos para la preparación y su uso | |
PE20170919A1 (es) | Formulacion inhalable | |
TR201716155A1 (tr) | Bir beta-2 agonisti ile birlikte bir kortikosteroid içeren farmasötik formülasyon. | |
PE20191491A1 (es) | Composicion de liberacion rapida de cinitaprida y simeticona y proceso para prepararla | |
CN302550275S (zh) | 割草机割草刀测试检具 | |
AR102108A1 (es) | Polvo seco para una formulación para inhalar que tiene una estabilidad mejorada de los principios activos combinados | |
CN302518780S (zh) | 灌装机 | |
UY35541A (es) | Composición de ácidos grasos omega-3, zinc y hierro para el tratamiento del trastorno por déficit de atención e hiperactividad (TDAH) | |
CN302061476S (zh) | 药品包装盒(藿香正气合剂) |